PE20131326A1 - Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico - Google Patents
Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionicoInfo
- Publication number
- PE20131326A1 PE20131326A1 PE2013000263A PE2013000263A PE20131326A1 PE 20131326 A1 PE20131326 A1 PE 20131326A1 PE 2013000263 A PE2013000263 A PE 2013000263A PE 2013000263 A PE2013000263 A PE 2013000263A PE 20131326 A1 PE20131326 A1 PE 20131326A1
- Authority
- PE
- Peru
- Prior art keywords
- formula
- compound
- procedure
- diaminopropionic acid
- enanthiomeric
- Prior art date
Links
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical class [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 abstract 1
- AQFLVLHRZFLDDV-VIFPVBQESA-N (1s)-1-phenylpropan-1-amine Chemical compound CC[C@H](N)C1=CC=CC=C1 AQFLVLHRZFLDDV-VIFPVBQESA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
SE REFIERE A UN PROCEDIMIENTO DE OBTENCION DE COMPUESTOS DERIVADOS DE ACIDO 2,3-DIAMINOPROPIONICO DE FORMULA (I) DONDE R1 ES H, F, Cl, ALQUILO(C1-C4), CN, ENTRE OTROS; R2 ES UN HETEROARILO TAL COMO PIRROL, PIRIDINA, PIRIMIDINA, TIAZOL, ENTRE OTROS, O ARILO TAL COMO FENILO, NAFTILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS; Y R3 ES H, ALQUILO(C1-C4), FENILO, ENTRE OTROS; DONDE DICHO PROCEDIMIENTO COMPRENDE: A) MEZCLAR UN COMPUESTO DE FORMULA (II) EN UN DISOLVENTE ORGANICO TAL COMO ACETATO DE N-BUTILO, ACETATO DE ETILO, DIISOPROPILETER, ENTRE OTROS, O UNA MEZCLA DE LOS MISMOS CON UN AUXILIAR ENANTIOMERICAMENTE PURO TAL COMO (S)-1-FENILETILAMINA, (R)-1- FENILETILAMINA, (S)-1-FENILPROPILAMINA, ENTRE OTROS, EN EL QUE LA RELACION MOLAR DEL COMPUESTO DE FORMULA (II) CON RESPECTO AL AUXILIAR ENANTIOMERICAMENTE PURO ES DE 0,5 A 1,1; B) SEPARAR LA SAL COMPUESTA DEL AUXILIAR ENANTIOMERICAMENTE PURO Y EL COMPUESTO DE FORMULA (I) MEDIANTE CRISTALIZACION FRACCIONADA; Y C) AISLAR EL COMPUESTO DE FORMULA (I) A PARTIR DE LA SAL COMPUESTA. LOS COMPUESTOS DE FORMULA (I) SON INTERMEDIOS PARA LA PREPARACION DE INHIBIDORES DE QUINASA IkB
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10305884 | 2010-08-12 | ||
| US201061428336P | 2010-12-30 | 2010-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20131326A1 true PE20131326A1 (es) | 2013-11-12 |
Family
ID=43598042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000263A PE20131326A1 (es) | 2010-08-12 | 2011-08-05 | Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8877926B2 (es) |
| EP (1) | EP2603491B1 (es) |
| JP (1) | JP6000248B2 (es) |
| KR (1) | KR20130099044A (es) |
| CN (1) | CN103209961A (es) |
| AR (1) | AR082621A1 (es) |
| AU (1) | AU2011288533A1 (es) |
| BR (1) | BR112013002985A2 (es) |
| CA (1) | CA2807979A1 (es) |
| CL (1) | CL2013000420A1 (es) |
| CO (1) | CO6690757A2 (es) |
| CR (1) | CR20130059A (es) |
| DO (1) | DOP2013000035A (es) |
| EC (1) | ECSP13012434A (es) |
| GT (1) | GT201300038A (es) |
| MA (1) | MA34464B1 (es) |
| MX (1) | MX2013001647A (es) |
| PE (1) | PE20131326A1 (es) |
| PH (1) | PH12013500256A1 (es) |
| RU (1) | RU2013110525A (es) |
| SG (1) | SG187791A1 (es) |
| TW (1) | TW201221504A (es) |
| UY (1) | UY33552A (es) |
| WO (1) | WO2012019967A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2787998T3 (en) | 2011-12-06 | 2017-02-06 | Sanofi Sa | Crystalline Forms of 2- (2-METHYLAMINOPYRIMIDIN-4-YL) -1H-INDOL-5-CARBOXYLIC ACID - [(S) -1-CARBAMOYL-2- (PHENYLPYRIMIDIN-2-YLAMINO) -ETHYL] -AMIDE |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19850301A1 (de) * | 1998-10-30 | 2000-05-04 | Basf Ag | Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren |
| DE19951360A1 (de) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| US7462638B2 (en) | 2002-08-17 | 2008-12-09 | Sanofi-Aventis Deutschland Gmbh | Use of IκB-kinase inhibitors in pain therapy |
| DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| DE102004033406A1 (de) * | 2004-07-10 | 2006-02-16 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten |
| US20070142417A1 (en) * | 2005-05-11 | 2007-06-21 | Aventis Pharmaceuticals Inc | Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor |
| DE102005025225A1 (de) | 2005-06-01 | 2006-12-07 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten |
-
2011
- 2011-08-05 CA CA2807979A patent/CA2807979A1/en not_active Abandoned
- 2011-08-05 EP EP11743050.4A patent/EP2603491B1/en active Active
- 2011-08-05 MA MA35657A patent/MA34464B1/fr unknown
- 2011-08-05 JP JP2013523574A patent/JP6000248B2/ja not_active Expired - Fee Related
- 2011-08-05 PH PH1/2013/500256A patent/PH12013500256A1/en unknown
- 2011-08-05 SG SG2013009899A patent/SG187791A1/en unknown
- 2011-08-05 KR KR1020137006179A patent/KR20130099044A/ko not_active Withdrawn
- 2011-08-05 RU RU2013110525/04A patent/RU2013110525A/ru not_active Application Discontinuation
- 2011-08-05 WO PCT/EP2011/063504 patent/WO2012019967A1/en not_active Ceased
- 2011-08-05 CN CN2011800493516A patent/CN103209961A/zh active Pending
- 2011-08-05 AU AU2011288533A patent/AU2011288533A1/en not_active Abandoned
- 2011-08-05 PE PE2013000263A patent/PE20131326A1/es not_active Application Discontinuation
- 2011-08-05 BR BR112013002985A patent/BR112013002985A2/pt not_active IP Right Cessation
- 2011-08-05 MX MX2013001647A patent/MX2013001647A/es unknown
- 2011-08-10 TW TW100128464A patent/TW201221504A/zh unknown
- 2011-08-10 UY UY0001033552A patent/UY33552A/es not_active Application Discontinuation
- 2011-08-10 AR ARP110102908A patent/AR082621A1/es unknown
-
2013
- 2013-02-08 EC ECSP13012434 patent/ECSP13012434A/es unknown
- 2013-02-11 CR CR20130059A patent/CR20130059A/es unknown
- 2013-02-11 CL CL2013000420A patent/CL2013000420A1/es unknown
- 2013-02-11 GT GT201300038A patent/GT201300038A/es unknown
- 2013-02-11 DO DO2013000035A patent/DOP2013000035A/es unknown
- 2013-02-11 US US13/763,975 patent/US8877926B2/en active Active
- 2013-03-08 CO CO13046970A patent/CO6690757A2/es unknown
-
2014
- 2014-09-30 US US14/502,141 patent/US9434696B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP13012434A (es) | 2013-03-28 |
| CN103209961A (zh) | 2013-07-17 |
| EP2603491B1 (en) | 2014-09-24 |
| GT201300038A (es) | 2015-06-24 |
| UY33552A (es) | 2012-03-30 |
| PH12013500256A1 (en) | 2013-03-18 |
| US9434696B2 (en) | 2016-09-06 |
| EP2603491A1 (en) | 2013-06-19 |
| RU2013110525A (ru) | 2014-09-20 |
| MA34464B1 (fr) | 2013-08-01 |
| CO6690757A2 (es) | 2013-06-17 |
| US20130211085A1 (en) | 2013-08-15 |
| DOP2013000035A (es) | 2013-03-15 |
| CL2013000420A1 (es) | 2013-04-05 |
| BR112013002985A2 (pt) | 2017-11-07 |
| WO2012019967A1 (en) | 2012-02-16 |
| TW201221504A (en) | 2012-06-01 |
| CA2807979A1 (en) | 2012-02-16 |
| AR082621A1 (es) | 2012-12-19 |
| US20150018554A1 (en) | 2015-01-15 |
| JP2013533296A (ja) | 2013-08-22 |
| SG187791A1 (en) | 2013-03-28 |
| MX2013001647A (es) | 2013-03-21 |
| US8877926B2 (en) | 2014-11-04 |
| AU2011288533A1 (en) | 2013-02-28 |
| CR20130059A (es) | 2013-03-25 |
| KR20130099044A (ko) | 2013-09-05 |
| JP6000248B2 (ja) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015007883A (es) | Compuestos para protección de células. | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| MX377552B (es) | Proceso para preparar un compuesto antiviral de formula i. | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| CA2875877C (en) | Syk inhibitors | |
| BRPI1009333B8 (pt) | compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| EP4295841A3 (en) | Sulfur (vi) fluoride compounds and their use in click-reaction | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| EA201291409A1 (ru) | Производные индолизина, способ их получения и их терапевтическое применение | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| EA201201179A1 (ru) | Способ получения изоксазолиновых производных | |
| UA111626C2 (uk) | Похідні дигідрохінолін-2-ону | |
| AR067413A1 (es) | Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer | |
| EA201690515A1 (ru) | Производные диазокарбазола в качестве пэт-лигандов белка tau | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| MY170652A (en) | Method for producing pest control agent | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| IN2014MN01521A (es) | ||
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR079496A1 (es) | Derivados de aril triazol heteroaromaticos como inhibidores de enzima pde10a | |
| EA201490722A1 (ru) | ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНОГО РЕЦЕПТОРА ГЛУТАМАТА mGluR5 | |
| UY32077A (es) | Inhibidores de quinasa tipo polo | |
| MX2012013332A (es) | Preparacion de intermediarios de posaconazol. | |
| PE20081700A1 (es) | Derivados de acido de piranona sustituidos como agentes para tratar el sindrome metabolico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |